{Reference Type}: Journal Article
{Title}: Genomic Screening for Pathogenic Transthyretin Variants Finds Evidence of Underdiagnosed Amyloid Cardiomyopathy From Health Records.
{Author}: Carry BJ;Young K;Fielden S;Kelly MA;Sturm AC;Avila JD;Martin CL;Kirchner HL;Fornwalt BK;Haggerty CM; ;
{Journal}: JACC CardioOncol
{Volume}: 3
{Issue}: 4
{Year}: Oct 2021
{Factor}: 8.422
{DOI}: 10.1016/j.jaccao.2021.07.002
{Abstract}: <B>BACKGROUND: </B>New treatments for transthyretin amyloidosis improve survival, but diagnosis remains challenging. Pathogenic or likely pathogenic (P/LP) variants in the transthyretin (TTR) gene are one cause of transthyretin amyloidosis, and genomic screening has been proposed to identify at-risk individuals. However, data on disease features and penetrance are lacking to inform the utility of such population-based genomic screening for TTR.<BR><B>OBJECTIVE: </B>This study characterized the prevalence of P/LP variants in TTR identified through exome sequencing and the burden of associated disease from electronic health records for individuals with these variants from a large (N = 134,753), primarily European-ancestry cohort.<BR><B>METHODS: </B>We compared frequencies of common disease features and cardiac imaging findings between individuals with and without P/LP TTR variants.<BR><B>RESULTS: </B>We identified 157 of 134,753 (0.12%) individuals with P/LP TTR variants (43% male, median age 52 [Q1-Q3: 37-61] years). Seven P/LP variants accounted for all observations, the majority being V122I (p.V142I; 113, 0.08%). Approximately 60% (n = 91) of individuals with P/LP TTR variants (all V122I) had African ancestry. Diagnoses of amyloidosis were limited (2 of 157 patients), although related heart disease diagnoses, including cardiomyopathy and heart failure, were significantly increased in individuals with P/LP TTR variants who were aged >60 years. Fourteen percent (7 of 49) of individuals aged ≥60 or older with a P/LP TTR variant had heart disease and ventricular septal thickness >1.2 cm, only one of whom was diagnosed with amyloidosis.<BR><B>CONCLUSIONS: </B>Individuals with P/LP TTR variants identified by genomic screening have increased odds of heart disease after age 60 years, although amyloidosis is likely underdiagnosed without knowledge of the genetic variant.